Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.2    
  

 
 

AMENDMENT NO. 2 TO LICENSE AND COLLABORATION AGREEMENT    
  

THIS AMENDMENT NO. 2 TO LICENSE AND COLLABORATION AGREEMENT (this "Amendment"), effective as of May 8, 2001 (the "Effective Date") is entered
into by and between THE IMMUNE RESPONSE CORPORATION, a Delaware corporation ("IRC"), and TRINITY MEDICAL GROUP
USA, INC., a Florida corporation ("Trinity"), with respect to the following facts. 

 
 

RECITALS    
  

        A. IRC and Trinity Medical Group, Co., Ltd., a Thai limited company ("Trinity Thailand"), entered into the License and Collaboration Agreement dated as of
September 15, 1995, which was amended on September 29, 2000, by the Amendment No. 1 to License and Collaboration Agreement (the "Amendment No. 1") (collectively the
"Agreement"). 

        B.
Pursuant to the Assignment Agreement dated as of August 3, 2000, between Trinity Thailand and Trinity, Trinity Thailand assigned to Trinity and Trinity assumed, all of Trinity
Thailand's rights and obligations under the Agreement. 

        C.
The parties now desire to amend the Agreement on the terms and conditions set forth below. 

        NOW,
THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the parties amend the Agreement and otherwise agree as follows: 

 
 

ARTICLE 1 AMENDMENT    
  

        1.1 Section 1.8 of the Agreement shall be deleted in its entirety and restated to read as follows: 

        "Manufacturing Cost" shall mean the fully-burdened cost, expressed on a per unit manufacturing basis, of manufacturing the Product,
together with the packaging thereof, including the cost of materials, direct labor and benefits, overhead, all as determined in accordance with generally accepted accounting principles ("GAAP"), and
excess capacity related cost, consistent with the manufacturer's accounting practices for other products manufactured. Materials, direct labor and benefits, overhead, and excess capacity related cost
shall be further defined as follows: 

        1.8.1"Materials" shall include those items which form an integral and direct part of the bulk form of the Product and are
necessary for its production, as well as cartons, labels, package inserts and shippers. 

        1.8.2"Direct Labor and Benefits" shall include that portion of basic wages, labor and related payroll taxes and employee
benefits spent in actual production of the particular Product which can be identified with or charged to the Product. 

        1.8.3"Overhead" shall include without limitation all operating expenses incurred by and in support of the particular
manufacturing cost centers, purchasing department and quality assurance operations, with respect to the Product, including without limitation the following: 

	•
	Indirect
labor, related payroll taxes and employee benefits

	•
	Depreciation

	•
	Taxes

	•
	Insurance

	•
	Rent

	•
	Repairs
and maintenance

	•
	Supplies

 

	•
	Utilities

	•
	Factory
administrative expenses 

        1.8.4"Excess Capacity Related Cost" shall include any and all costs, as defined in Sections
1.8.1 - 1.8.3 above, that are associated with underutilization of REMUNETM plant capacity that may otherwise be charged to expense in the period incurred. 

        1.2  Section 1.18
shall be added to the Agreement as follows: 

        1.18 "Production" shall mean the actual production, as determined at the end of each month, of IRC's current and future
manufacturing facility(s) which produces the Product. 

        1.3  Section 6.1.2
of the Agreement shall be deleted in its entirety and restated to read as follows: 

        For Commercial Sale and Distribution. IRC shall manufacture, sell and deliver to Trinity such amounts of the Product, as Trinity
reasonably requests pursuant to the provisions of Section 6.4 below, equal to Trinity's requirement of the Product for commercial sale and distribution in the Territory for use in the Field, up
to twenty-five percent (25%) of IRC's Production for the Product. In the event Trinity's requirement of the Product for commercial sale and distribution in the Territory for use in the
Field exceeds twenty-five percent (25%) of IRC's Production for the Product, Trinity may request such additional amounts of the Product pursuant to the provisions of Section 6.4
below, and IRC, in its sole
discretion, may decide to manufacture, sell and deliver to Trinity such additional amounts of the Product. 

        1.4  Sections
6.3.1(a), (c) and (d) of the Agreement shall be deleted in their entirety and restated to read as follows: 

        (a)  With
respect to clinical development supply under Section 6.1.1 above, after receipt of approval from the governing health authority of Thailand to conduct the
applicable human clinical trials in Thailand and approval from the FDA to supply the Product for use therein, IRC shall supply Trinity with such 100 microgram and DTH skin testing doses of the Product
and placebo (as set forth in mutually acceptable protocols), for use in human clinical trials in Thailand under the Development Program for a period not to exceed three (3) years after the
commencement of human clinical trials in Thailand. IRC shall supply such doses of Product and placebo for use in such human clinical trials in Thailand for not more than 10,000 enrolled patients
during such period at no cost to Trinity. If additional Product and placebo is required for use in human clinical trials in Thailand prior to the First Commercial Sale, IRC shall supply such
additional Product and placebo as the parties mutually agree in writing, at a purchase price equal to one hundred and ten percent (110%) of IRC's Manufacturing Cost for the Product and at such
purchase price as the parties mutually agree in writing for placebo. 

        (c)  With
respect to commercial supply under Section 6.1.2 above, Trinity shall purchase Product from IRC at a price equal to one hundred and ten percent (110%) of
IRC's Manufacturing Cost for such Product. 

        (d)  IRC
shall calculate its Manufacturing Cost for the Product in good faith in a manner which reasonably and equitably allocates the cost of Materials, Direct Labor and
Benefits, Overhead, and Excess Capacity Related Cost (each as defined in Section 1.8 above) to the Product. 

        1.5  Article 7
of the Agreement shall be deleted in its entirety. 

2

 

        1.6  Article 8
of the Agreement shall be deleted in its entirety and restated to read as follows: 

 
 

ARTICLE 8
  REPORTS AND ACCOUNTING    
  

        8.1  Reports, Exchange Rates. During the term of the Agreement following the First Commercial Sale of the Product, Trinity
shall furnish to IRC a quarterly written report showing in reasonably specific detail, on a country by country basis, (a) the quantity of all Product sold or distributed by Trinity, its
Affiliates and its sublicensees in the Territory during the reporting period; (b) the withholding taxes, if any, required by law with respect to such sale or distribution; and (c) the
date of the First Commercial Sale of the Product in each country in the Territory during the reporting period. Reports shall be due on the thirtieth (30th) day following the close of each quarter.
Trinity shall keep complete and accurate records in sufficient detail to properly reflect all sales and distributions of the Product. 

        8.2  Audits for IRC

        8.2.1
Upon the written request of IRC and not more than twice in each calendar year, Trinity shall permit an independent certified public accounting firm of internationally recognized
standing, selected by IRC and reasonably acceptable to Trinity, at IRC's expense, to have access during normal business hours to such records of Trinity as may be reasonably necessary to verify the
accuracy of the reports hereunder for any year ending not more than thirty-six (36) months prior to the date of such request. The accounting firm shall disclose to IRC only whether
the records are correct or not and the specific details concerning any discrepancies. No other information shall be shared. 

        8.2.2
Trinity shall include in each permitted sublicense granted by it pursuant to the Agreement a provision requiring the sublicensee to make reports to Trinity, to keep and maintain
records of sales and distributions made pursuant to such sublicense and to grant access to such records by IRC's independent accountant to the same extent required of Trinity under the Agreement. 

        8.3  Audits for Trinity

        8.3.1
Upon the written request of Trinity and not more than twice in each calendar year, IRC shall permit an independent certified public accounting firm of internationally recognized
standing, selected by Trinity and reasonably acceptable to IRC, at Trinity's expense, to have access during normal business hours to such records of IRC as may be reasonably necessary to verify the
accuracy and the propriety of the amounts charged, consistent with Manufacturing Cost, of any invoices hereunder for any year ending not more than thirty-six (36) months prior to
the date of such request. Trinity shall also have access to such records of IRC, under the same terms and conditions as provided for the audit of IRC's invoices to Trinity, as may be reasonably
necessary to verify IRC's Production. The accounting firm shall disclose to Trinity only whether the records are correct or not and the specific details concerning any discrepancies. No other
information shall be shared. 

        8.4  Confidential Financial Information. Each party shall treat all of the other party's financial information subject to
review under this Article 8 or under any sublicense agreement as confidential, and shall cause its accounting firm to retain all such financial information in confidence. 

        1.6  Sections
9.1, 9.3, and 9.5 shall be deleted in its entirety. 

3

 

        1.7  Section 11.2
of the Agreement shall be deleted in its entirety and restated to read as follows: 

        Termination by IRC. This Agreement shall terminate, at the option of IRC effective upon written notice thereof to Trinity, if Trinity has
not received the required marketing approval from the governing health authority of Thailand for the Product on or before August 31, 2004. 

 
 

ARTICLE 2
  MISCELLANEOUS    
  

        2.1  Defined Terms. All terms used, but not defined, in this Amendment shall have the respective meanings set forth in the
Agreement. 

        2.2  Continuing Effect. This Amendment shall be effective for all purposes as of the Effective Date. Except as otherwise
expressly modified by this Amendment, the Agreement shall remain in full force and effect in accordance with its terms. 

        2.3  Governing Law. This Amendment shall be governed by and construed in accordance with the laws of the State of California,
without regard to the conflicts of law, principles thereof, and shall not be governed by the United Nations Convention on Contracts for the International Sale of Goods. 

        2.4  Counterparts. This Amendment may be executed in counterparts, each of which shall be deemed to be an original and
together shall be deemed to be one and the same document. 

        IN
WITNESS WHEREOF, the undersigned have duly executed and delivered this Amendment effective as of the Effective Date. 

	 	 	THE IMMUNE RESPONSE CORPORATION
	

 	
 	

By	
 	

 Dennis J. Carlo, Ph. D.

President and Chief Executive Officer
	

 	
 	

TRINITY MEDICAL GROUP USA, INC.
	

 	
 	

By	
 	

	

 	
 	

Title	
 	

	

 	
 	

By	
 	

	

 	
 	

Title	
 	

4

QuickLinks

Exhibit 10.2

AMENDMENT NO. 2 TO LICENSE AND COLLABORATION AGREEMENT

RECITALS

ARTICLE 1 AMENDMENT

ARTICLE 8 REPORTS AND ACCOUNTING

ARTICLE 2 MISCELLANEOUSQuickLinks
 -- Click here to rapidly navigate through this document
  

 
 

Exhibit 10.6    
  

 
 

AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENT    
  

        THIS AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENT (this "Amendment"), effective as of June 26, 2002 (the "Effective
Date") is entered into by and between THE IMMUNE RESPONSE CORPORATION, a Delaware corporation (the "Company"), and TRINITY
MEDICAL GROUP USA, INC., a Florida corporation (the "Investor"), with respect to the following facts. 

RECITALS  

        A.    IRC
and Trinity Medical Group, Co., Ltd., a Thai limited company ("Trinity Thailand"), entered into the Stock Purchase Agreement dated as of September 15,
1995 (the "Agreement"). 

        B.    Pursuant
to the Assignment Agreement dated as of August 3, 2000, between Trinity Thailand and the Investor, Trinity Thailand assigned to the Investor and the
Investor assumed, all of Trinity Thailand's rights and obligations under the Agreement. 

        C.    The
parties now desire to amend the Agreement on the terms and conditions set forth below. 

        NOW,
THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the parties amend the Agreement and otherwise agree as follows: 

ARTICLE 1

AMENDMENT  

        1.1  Section 1.1
of the Agreement is restated in its entirety to read as follows: 

        1.1    Sale and Issuance of Shares.    On the terms and subject to the conditions of the Agreement, the Investor shall
purchase, and the Company shall sell and issue to the Investor, the following number of shares (the "Shares") of the Company's common stock on the following dates (each a "Closing Date") at the
following purchase price (the "Purchase Price"): 

        1.1.1    The
Investor shall purchase, and the Company shall sell and issue to the Investor, 333,334 Shares at the Purchase Price of US$15.00 per share, on April 30, 1996
(the "First Closing Date"); and 

        1.1.2    The
Investor shall purchase, and the Company shall sell and issue to the Investor, 2,000,000 Shares at the Purchase Price of US$2.50 per share, on the date that is
thirty (30) days after the date on which the Investor receives the required marketing approval from the governing health authority of Thailand for the Product (the "Second Closing Date"). 

        1.2    Section 2.10
of the Agreement is restated in its entirety to read as follows: 

        2.10    The
Company (a) is a "domestic issuer" and a "reporting issuer" (as such terms are defined in Rule 902 of Regulation S), and (b) has filed
all material required to be filed by it pursuant to the requirements of Section 13(a) or 15(d) of the 1934 Act for at least the twelve (12) months immediately preceding the date hereof.
The Common Stock trades on the Nasdaq Stock Market. 

ARTICLE 2

REGISTRATION RIGHTS  

        2.1  At
the request of the Investor, the Company agrees to file a registration statement under the Securities Act of 1933, as amended (the "Act"), with the Securities
and Exchange Commission ("SEC") to register the Shares issued pursuant to Section 1.1.2 of the Agreement (as amended hereby), as soon 

1

 

as practicable after the Second Closing Date and upon receipt of the request of the Investor. The Company shall use reasonable commercial efforts to respond to comments of the SEC within ten
(10) business days of receipt of said comments and will use commercially reasonable efforts to cause the registration statement to be declared effective by the SEC within ninety
(90) days of the receipt of the request from the Investor. The Company shall keep the registration statement continuously effective until the date occurring one year following the date on which
the Shares were issued to the Investor pursuant to Section 1.1.2 of the Agreement (as amended hereby). The Company shall cause the related prospectus to be amended or supplemented by a required
prospectus supplement pursuant to Rule 424 under the Act. Notwithstanding the foregoing, the Company may delay the filing of the registration statement for 180 days after receipt of the
request from the Investor, if it furnishes to the Investor a certificate signed by the Chairman of the Board of Directors of the Company stating, that in the good faith judgment of the Board of
Directors of the Company, it would be seriously detrimental to the Company and its stockholders for such registration statement to be filed and that it is therefore, essential to delay the filing of
the registration statement. 

        2.2  In
addition, the Company hereby grants to the Investor piggyback registration rights with respect to the Shares issued to the Investor pursuant to Section 1.1.2
of the Agreement (as amended hereby) as set forth below. In the event the Company is filing a registration statement for itself or on behalf of any of its stockholders, the Company shall notify the
Investor in writing reasonably in advance of such filing (but at least five business days) and give the Investor the opportunity to include all or any part of such Shares in the registration
statement. If a registration statement under which the Company gives notice under this Article 2.2 is for an underwritten offering, then the Company shall so advise the Investor in the notice.
In such event, the right of the Investor to include any of such Shares in a registration pursuant to this Article 2.2 shall be conditioned upon the Investor's participation in such
underwriting. The Investor shall enter into an underwriting agreement in customary form with the managing underwriter or underwriter(s) selected for such underwriting. Notwithstanding any other
provision of this Article 2.2, if the underwriter(s) determine(s) in good faith that market factors require a limitation of the number of shares to be underwritten, then the underwriter(s) may
exclude shares from the registration and the underwriting, and the number of shares that may be included in the registration and the underwriting shall be allocated, first,  to the Company, and
second, on a pro rata basis, amongst the Shares issued to the Investor pursuant to Section 1.1.2 of
the Agreement (as amended hereby) and any shares held by other stockholders of the Company who have piggyback registration rights. 

ARTICLE 3

MISCELLANEOUS  

        3.1  All
terms used, but not defined, in this Amendment shall have the respective meanings set forth in the Agreement. 

        3.2  This
Amendment shall be effective for all purposes as of the Effective Date. Except as otherwise expressly modified by this Amendment, the Agreement shall remain in full
force and effect in accordance with its terms. 

        3.3  This
Amendment shall be governed by, interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. 

        3.4  This
Amendment may be executed in counterparts, each of which shall be deemed to be an original and together shall be deemed to be one and the same document. 

2

 

        IN
WITNESS WHEREOF, the parties have caused this Amendment to be executed by their respective duly authorized officers as of the Effective Date. 

	 	 	THE IMMUNE RESPONSE CORPORATION
	

 	
 	

By	
 	

 
	 	 	 	 	
 Dr. Dennis J. Carlo
 President and CEO
	

 	
 	

TRINITY MEDICAL GROUP USA, INC.
	

 	
 	

By	
 	

 
	 	 	 	 	
President
	

 	
 	

By	
 	

 
	 	 	 	 	
Chief Executive Officer

3

QuickLinks

Exhibit 10.6

AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00040-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00040-of-00352.parquet"}]]